› Forums › General Melanoma Community › OncoSec helps 57% of non-responders to immunotherpy become responders
- This topic is empty.
- Post
-
- December 31, 2017 at 4:25 am
Interesting findings: https://seekingalpha.com/article/4122712-oncosec-presses-forward-positive-melanoma-combo-study
"The phase 2 results showed that the patients in the trial that took the combo therapy (ImmunoPulse IL-12 and Keytruda) achieved a 57% progression-free survival rate at 15 months. That is pretty impressive, especially when you consider the fact that these patients didn't respond at all with an anti-PD-1 alone. What's even better is the fact that 11 out of 11 or 100% of the patients had a duration of response. In addition, the median PFS has not yet been reached."
- You must be logged in to reply to this topic.